Skip to content
2000
Volume 28, Issue 16
  • ISSN: 1386-2073
  • E-ISSN: 1875-5402

Abstract

Background

Constipation-predominant irritable bowel syndrome (IBS-C) is a chronic functional intestinal disease that can significantly reduce patients' quality of life.

Objective

This study aims to evaluate the clinical effect and mechanism of YunPi RouGan (YPRG) prescription on IBS-C patients with liver-depression and spleen-deficiency syndrome.

Methods

42 IBS-C patients receiving treatment at Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine from May 2022 to March 2023 were recruited and randomly assigned to either the treatment or control group, with 21 patients in each group. The patients received either a YPRG prescription or a linalotide capsule for 4 weeks. A series of scales were utilized to evaluate the clinical symptoms, psychological aspects, and quality of life in IBS patients. Meanwhile, fresh fecal samples were collected to analyze the changes in gut microbiota by 16SrDNA sequencing.

Results

In terms of clinical treatment, both YPRG prescription and the first-line drug linaclotide have similar effects for IBS-C. However, YPRG prescription has demonstrated significant improvements in several symptoms, such as abdominal distension and belching. Furthermore, it has been shown to upregulate the diversity of gut microbiota and induce changes in the types of dominant microbiota in IBS-C patients. At the phylum level, Firmicutes and Bacteroides increased, while Proteobacteria, actinobacteria, and desulphurobacteria decreased. At the genus level, Bacteroides, Spirillum, Clostridium praxis, Roxella, Para-salmonella, Haemophilus, koala bacillus, Micrococcus rare, Spirillum, and Streptococcus increased significantly.

Conclusion

The effect of YPRG prescription on improving the clinical symptoms of IBS-C may be attributed to its potential to regulate gut microbiota.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cchts/10.2174/0113862073302157240920115002
2024-10-09
2026-02-24

  • From This Site

    /content/journals/cchts/10.2174/0113862073302157240920115002
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ZhangT. ZhangC. ZhangJ. SunF. DuanL. Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.Front. Cell. Infect. Microbiol.20221285996710.3389/fcimb.2022.859967 35433498
     [Google Scholar]
  2. Patel, N; Shackelford, KB Irritable Bowel Syndrome; StatPearls: Treasure Island (FL), 2024.
  3. FordA.C. SperberA.D. CorsettiM. CamilleriM. Irritable bowel syndrome.Lancet2020396102631675168810.1016/S0140‑6736(20)31548‑8 33049223
     [Google Scholar]
  4. SiddiquiS. CashB.D. Tenapanor for constipation-predominant irritable bowel syndrome.Drugs Today (Barc)202056320321010.1358/dot.2020.56.3.3115214 32282867
     [Google Scholar]
  5. Sebastián DomingoJ.J. Irritable bowel syndrome.Med. Clín. (Barc.)202215827681 34238582
     [Google Scholar]
  6. BlackC.J. FordA.C. Global burden of irritable bowel syndrome: trends, predictions and risk factors.Nat. Rev. Gastroenterol. Hepatol.202017847348610.1038/s41575‑020‑0286‑8 32296140
     [Google Scholar]
  7. SahaL. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine.World J. Gastroenterol.201420226759677310.3748/wjg.v20.i22.6759 24944467
     [Google Scholar]
  8. BonettoS. FagooneeS. BattagliaE. GrassiniM. SaraccoG.M. PellicanoR. Recent advances in the treatment of irritable bowel syndrome.Polish Arch. Internal Med.20211317-870971510.20452/pamw.16067 34463082
     [Google Scholar]
  9. HuangK.Y. WangF.Y. LvM. MaX.X. TangX.D. LvL. Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment.World J. Gastroenterol.202329264120413510.3748/wjg.v29.i26.4120 37475846
     [Google Scholar]
  10. LiL. CuiH. LiT. QiJ. ChenH. GaoF. TianX. MuY. HeR. LvS. ChuF. XuB. WangP. LeiH. XuH. WangC. Synergistic effect of berberine-based chinese medicine assembled nanostructures on diarrhea-predominant irritable bowel syndrome in vivo.Front. Pharmacol.202011121010.3389/fphar.2020.01210 32982718
     [Google Scholar]
  11. ChenG. XieX. PengC. Treatment of irritable bowel syndrome by chinese medicine: A review.Chin. J. Integr. Med.202329437738410.1007/s11655‑021‑3521‑4 34546535
     [Google Scholar]
  12. ZhongW. HeJ. HuangW. YinG. LiuG. CaoY. MiaoJ. Effect of the phosphorylation structure in casein phosphopeptides on the proliferation, differentiation, and mineralization of osteoblasts and its mechanism.Food Funct.20231422101071011810.1039/D3FO03125J 37874279
     [Google Scholar]
  13. LuoY. WangC.Z. Hesse-FongJ. LinJ.G. YuanC.S. Application of chinese medicine in acute and critical medical conditions.Am. J. Chin. Med.20194761223123510.1142/S0192415X19500629 31505937
     [Google Scholar]
  14. LiH. TianY.Z. XiaJ.Q. Clinical study on the treatment of 63 cases of constipation-type irritable bowel syndrome with “Yunpi Ruogan Prescription”.Jiangsu Traditi. Chin. Med.201749103032
     [Google Scholar]
  15. HanningN. EdwinsonA.L. CeuleersH. PetersS.A. De ManJ.G. HassettL.C. De WinterB.Y. GroverM. Intestinal barrier dysfunction in irritable bowel syndrome: A systematic review.Therap. Adv. Gastroenterol.20211410.1177/1756284821993586 33717210
     [Google Scholar]
  16. PimentelM. LemboA. Microbiome and Its Role in Irritable Bowel Syndrome.Dig. Dis. Sci.202065382983910.1007/s10620‑020‑06109‑5 32026278
     [Google Scholar]
  17. YangY. FangJ. GuoX. DaiN. ShenX. YangY. SunJ. BhandariB.R. ReasnerD.S. CroninJ.A. CurrieM.G. JohnstonJ.M. ZengP. MontreewasuwatN. ChenG.Z. LimS. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.J. Gastroenterol. Hepatol.201833598098910.1111/jgh.14086 29319191
     [Google Scholar]
  18. ZhengXY guiding principle of clinical research on new drugs of traditional chinese medicine (Trial).2002
     [Google Scholar]
  19. SinghP. AlmE.J. KelleyJ.M. ChengV. SmithM. KassamZ. NeeJ. IturrinoJ. LemboA. Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D.Gut Microbes2022141202006710.1080/19490976.2021.2020067 35014601
     [Google Scholar]
  20. YueT. LiQ. WangR. LiuZ. GuoM. BaiF. ZhangZ. WangW. ChengY. WangH. Comparison of hospital anxiety and depression scale (HADS) and zung self-rating anxiety/depression scale (SAS/SDS) in evaluating anxiety and depression in patients with psoriatic arthritis.Dermatology2020236217017810.1159/000498848 31434087
     [Google Scholar]
  21. Di RosaC. AltomareA. TerrignoV. CarboneF. TackJ. CicalaM. GuarinoM. Constipation-predominant irritable bowel syndrome (IBS-C): Effects of different nutritional patterns on intestinal dysbiosis and symptoms.Nutrients2023157164710.3390/nu15071647 37049488
     [Google Scholar]
  22. ChangL. SultanS. LemboA. VerneG.N. SmalleyW. HeidelbaughJ.J. AGA Clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation.Gastroenterology2022163111813610.1053/j.gastro.2022.04.016 35738724
     [Google Scholar]
  23. ZengX. HeJ. LiX. ChenP. ZuoJ. CaiX. FanZ. QuJ. Clinical efficacy of one-finger meditation massage on IBS-C based on the “gut-brain axis” theory: Study protocol for a randomized controlled trial.BMC Complement. Med. Ther.202323118510.1186/s12906‑023‑04019‑3 37280574
     [Google Scholar]
  24. XuX.M. YangZ. TianY.Z. AnZ.T. WangY.S. LiH. Study on the effect of Xi-Feng-Hua-Shi granules on intestinal flora in patients with diarrhea-predominant irritable bowel syndrome based on 16S rDNA sequencing.Microenviron. Microecol. Res.2022442010.53388/MMR2022020
     [Google Scholar]
  25. HuZ. LiM. YaoL. WangY. WangE. YuanJ. WangF. YangK. BianZ. ZhongL.L.D. The level and prevalence of depression and anxiety among patients with different subtypes of irritable bowel syndrome: A network meta-analysis.BMC Gastroenterol.20212112310.1186/s12876‑020‑01593‑5 33413140
     [Google Scholar]
  26. XueD. ZhangY. SongZ. JieX. JiaR. ZhuA. Integrated meta-analysis, data mining, and animal experiments to investigate the efficacy and potential pharmacological mechanism of a TCM tonic prescription, Jianpi Tongmai formula, in depression.Phytomedicine202210515434410.1016/j.phymed.2022.154344 35932605
     [Google Scholar]
  27. DuL. ZhangZ. ZhaiL. XuS. YangW. HuangC. LinC. ZhongL.L.D. BianZ. ZhaoL. Altered gut microbiota–host bile acid metabolism in IBS-D patients with liver depression and spleen deficiency pattern.Chin. Med.20231818710.1186/s13020‑023‑00795‑9 37468912
     [Google Scholar]
  28. XuW. ZhangZ. LuY. LiM. LiJ. TaoW. Traditional Chinese medicine Tongxie Yaofang treating irritable bowel syndrome with diarrhea and type 2 diabetes mellitus in rats with liver-depression and spleen-deficiency: A preliminary study.Front. Nutr.2022996893010.3389/fnut.2022.968930 36438735
     [Google Scholar]
  29. SinghR. ZoggH. WeiL. BartlettA. GhoshalU.C. RajenderS. RoS. Gut microbial dysbiosis in the pathogenesis of gastrointestinal dysmotility and metabolic disorders.J. Neurogastroenterol. Motil.2021271193410.5056/jnm20149 33166939
     [Google Scholar]
  30. van ThielI.A.M. de JongeW.J. ChiuI.M. van den WijngaardR.M. Microbiota-neuroimmune cross talk in stress-induced visceral hypersensitivity of the bowel.Am. J. Physiol. Gastrointest. Liver Physiol.20203186G1034G104110.1152/ajpgi.00196.2019 32308040
     [Google Scholar]
  31. SadowskiD.C. CamilleriM. CheyW.D. Canadian association of gastroenterology clinical practice guideline on the management of bile acid diarrhea.Clin. Gastroenterol. Hepatol.20201812441
     [Google Scholar]
  32. PittayanonR. LauJ.T. YuanY. Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic.Review Gastroenterology201915719710810.1053/j.gastro.2019.03.049 30940523
     [Google Scholar]
  33. AzizM. KumarJ. Muhammad NawawiK. Raja AliR. MokhtarN. Irritable Bowel Syndrome, Depression, and Neurodegeneration: A Bidirectional Communication from Gut to Brain.Nutrients2021139306110.3390/nu13093061 34578939
     [Google Scholar]
  34. WangY. MaW. MehtaR. NguyenL.H. SongM. DrewD.A. AsnicarF. HuttenhowerC. SegataN. WolfJ. SpectorT. BerryS. StallerK. ChanA.T. Diet and gut microbial associations in irritable bowel syndrome according to disease subtype.Gut Microbes2023152226213010.1080/19490976.2023.2262130 37786251
     [Google Scholar]
  35. WeiW. WangH.F. ZhangY. ZhangY.L. NiuB.Y. YaoS.K. Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome.World J. Gastroenterol.202026457153717210.3748/wjg.v26.i45.7153 33362374
     [Google Scholar]
  36. GargariG. TavernitiV. GardanaC. CremonC. CanducciF. PaganoI. BarbaroM.R. BellacosaL. CastellazziA.M. ValsecchiC. TagliacarneS.C. BelliniM. BertaniL. GambacciniD. MarchiS. CicalaM. GermanàB. Dal PontE. VecchiM. OgliariC. FioreW. StanghelliniV. BarbaraG. GuglielmettiS. Fecal Clostridiales distribution and short‐chain fatty acids reflect bowel habits in irritable bowel syndrome.Environ. Microbiol.20182093201321310.1111/1462‑2920.14271 29749705
     [Google Scholar]
  37. LabusJ.S. OsadchiyV. HsiaoE.Y. TapJ. DerrienM. GuptaA. TillischK. Le NevéB. GrinsvallC. LjungbergM. ÖhmanL. TörnblomH. SimrenM. MayerE.A. Evidence for an association of gut microbial Clostridia with brain functional connectivity and gastrointestinal sensorimotor function in patients with irritable bowel syndrome, based on tripartite network analysis.Microbiome2019714510.1186/s40168‑019‑0656‑z 30898151
     [Google Scholar]
  38. TapJ. DerrienM. TörnblomH. BrazeillesR. Cools-PortierS. DoréJ. StörsrudS. Le NevéB. ÖhmanL. SimrénM. Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome.Gastroenterology20171521111123.e810.1053/j.gastro.2016.09.049 27725146
     [Google Scholar]
  39. XiaoL. LiuQ. LuoM. XiongL. Gut microbiota-derived metabolites in irritable bowel syndrome.Front. Cell. Infect. Microbiol.20211172934610.3389/fcimb.2021.729346 34631603
     [Google Scholar]
  40. CanakisA. HaroonM. WeberH.C. Irritable bowel syndrome and gut microbiota.Curr. Opin. Endocrinol. Diabetes Obes.2020271283510.1097/MED.0000000000000523 31789724
     [Google Scholar]
  41. CheyW.D. KurlanderJ. EswaranS. Irritable bowel syndrome: A clinical review.JAMA2015313994995810.1001/jama.2015.0954 25734736
     [Google Scholar]
  42. Navarro-TapiaE. Almeida-ToledanoL. SebastianiG. Serra-DelgadoM. García-AlgarÓ. Andreu-FernándezV. Effects of microbiota imbalance in anxiety and eating disorders: probiotics as novel therapeutic approaches.Int. J. Mol. Sci.2021225235110.3390/ijms22052351 33652962
     [Google Scholar]
  43. EsgalhadoM. KempJ.A. DamascenoN.R.T. FouqueD. MafraD. Short-chain fatty acids: A link between prebiotics and microbiota in chronic kidney disease.Future Microbiol.201712151413142510.2217/fmb‑2017‑0059 29027814
     [Google Scholar]
  44. VicentiniF.A. KeenanC.M. WallaceL.E. WoodsC. CavinJ.B. FlocktonA.R. MacklinW.B. Belkind-GersonJ. HirotaS.A. SharkeyK.A. Intestinal microbiota shapes gut physiology and regulates enteric neurons and glia.Microbiome20219121010.1186/s40168‑021‑01165‑z 34702353
     [Google Scholar]
  45. GeX. PanJ. LiuY. WangH. ZhouW. WangX. Intestinal Crosstalk between Microbiota and Serotonin and its Impact on Gut Motility.Curr. Pharm. Biotechnol.201819319019510.2174/1389201019666180528094202 29804531
     [Google Scholar]
  46. MaleszaI.J. MaleszaM. WalkowiakJ. MussinN. WalkowiakD. AringazinaR. Bartkowiak-WieczorekJ. MądryE. High-Fat, Western-Style Diet, Systemic Inflammation, and Gut Microbiota: A Narrative Review.Cells20211011316410.3390/cells10113164 34831387
     [Google Scholar]
  47. TilgH. ZmoraN. AdolphT.E. ElinavE. The intestinal microbiota fuelling metabolic inflammation.Nat. Rev. Immunol.2020201405410.1038/s41577‑019‑0198‑4 31388093
     [Google Scholar]
  48. HeY. XuR. WangW. ZhangJ. HuX. Probiotics, prebiotics, antibiotic, Chinese herbal medicine, and fecal microbiota transplantation in irritable bowel syndrome.Medicine (Baltimore)20209932e2150210.1097/MD.0000000000021502 32769886
     [Google Scholar]
  49. XiaX. XieY. ChenQ. DingD. WangZ. XuY. WangY. WangX. DingW. Cocultivation of Chinese prescription and intestine microbiota: SJZD alleviated the major symptoms of IBS-D subjects by tuning neurotransmitter metabolism.Front. Endocrinol. (Lausanne)202213105310310.3389/fendo.2022.1053103 36452327
     [Google Scholar]
  50. ChenS.Y. ZhouQ.Y.J. ChenL. LiaoX. LiR. XieT. The Aurantii Fructus Immaturus flavonoid extract alleviates inflammation and modulate gut microbiota in DSS-induced colitis mice.Front. Nutr.20229101389910.3389/fnut.2022.1013899 36276817
     [Google Scholar]
  51. LinC.L. YingT.H. YangS.F. LinC.L. ChiouH.L. HsiehY.H. Magnolin targeting of the JNK/Sp1/MMP15 signaling axis suppresses cervical cancer microenvironment and metastasis via microbiota modulation.Cancer Lett.202458321658410.1016/j.canlet.2023.216584 38123014
     [Google Scholar]
  52. XueZ. WuC. WeiJ. XianM. WangT. YangB. ChenM. An orally administered magnoloside A ameliorates functional dyspepsia by modulating brain-gut peptides and gut microbiota.Life Sci.201923311674910.1016/j.lfs.2019.116749 31412264
     [Google Scholar]
  53. BaiY. WangS. WangX. WengY. FanX. ShengH. ZhuX. LouL. ZhangF. The flavonoid-rich Quzhou Fructus Aurantii extract modulates gut microbiota and prevents obesity in high-fat diet-fed mice.Nutr. Diabetes2019913010.1038/s41387‑019‑0097‑6 31645541
     [Google Scholar]
  54. HuangM. Cople-RodriguesC.S. WaitzbergD.L. RochaI.M.G. CurioniC.C. Changes in the gut microbiota after the use of herbal medicines in overweight and obese individuals: A systematic review.Nutrients2023159220310.3390/nu15092203 37432344
     [Google Scholar]
  55. TuohongerbiekeA. WangH. WuJ. WangZ. DongT. HuangY. ZhuD. SunD. TsimK.W.K. Xiao Cheng Qi Decoction, an ancient chinese herbal mixture, relieves loperamide-induced slow-transit constipation in mice: An action mediated by gut microbiota.Pharmaceuticals (Basel)202417215310.3390/ph17020153 38399368
     [Google Scholar]
  56. WangK. GuoJ. ChangX. GuiS. Painong-San extract alleviates dextran sulfate sodium-induced colitis in mice by modulating gut microbiota, restoring intestinal barrier function and attenuating TLR4/NF-κB signaling cascades.J. Pharm. Biomed. Anal.202220911452910.1016/j.jpba.2021.114529 34915325
     [Google Scholar]
  57. NieX. GengZ. LiuJ. QiL. WangZ. LiuT. TangJ. Chinese herbal medicine anticancer cocktail soup activates immune cells to kill colon cancer cells by regulating the gut microbiota-Th17 axis.Front. Pharmacol.20221396363810.3389/fphar.2022.963638 36147322
     [Google Scholar]
  58. LiJ. LiD. ChenY. ChenW. XuJ. GaoL. Gut microbiota and aging: Traditional chinese medicine and modern medicine.Clin. Interv. Aging20231896398610.2147/CIA.S414714 37351381
     [Google Scholar]
  59. BuF. TuY. WanZ. TuS. Herbal medicine and its impact on the gut microbiota in colorectal cancer.Front. Cell. Infect. Microbiol.202313109600810.3389/fcimb.2023.1096008 37469598
     [Google Scholar]
  60. BiZ. ZhengY. YuanJ. BianZ. The efficacy and potential mechanisms of chinese herbal medicine on irritable bowel syndrome.Curr. Pharm. Des.2017233451635172 28828984
     [Google Scholar]
  61. ZhangM. ZhengY. LiX. WuH. LiuP. ZhangK. ShiZ. LvM. WangF. TangX. Tong-Xie-Yao-Fang alleviates diarrhea-predominant irritable bowel syndrome in rats via the GCN2/PERK-eIF2α-ATF4 signaling pathway.Phytomedicine202210715435010.1016/j.phymed.2022.154350 36194974
     [Google Scholar]
  62. LiangS.B. HanM. ChengH.J. ZhangQ.Y. ZhangN.W. JiaB.Y. RobinsonN. LiuJ.P. Chinese herbal formula Tongxie Yaofang for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized, multiple-blind, placebo-controlled trial.Trials202223122610.1186/s13063‑022‑06142‑x 35313933
     [Google Scholar]
  63. BaiC. WangJ. WangY. LiuH. LiJ. WangS. BaiZ. GuoR. Exploration of the mechanism of Traditional Chinese Medicine for anxiety and depression in patients with diarrheal irritable bowel syndrome based on network pharmacology and meta-analysis.Front. Pharmacol.202415140473810.3389/fphar.2024.1404738 38835657
     [Google Scholar]
  64. LiC.Q. HeL.C. DongH.Y. JinJ.Q. Screening for the anti-inflammatory activity of fractions and compounds from Atractylodes macrocephala koidz.J. Ethnopharmacol.2007114221221710.1016/j.jep.2007.08.002 17869038
     [Google Scholar]
  65. Fernández-LázaroD. Seco-CalvoJ. Pascual-FernándezJ. Domínguez-OrtegaC. Del Valle SotoM. Mielgo-AyusoJ. 6-Week Supplementation with Tribulus terrestris L. to Trained Male CrossFit® Athletes on Muscle, Inflammation, and Antioxidant Biomarkers: A Randomized, Single-Blind, Placebo-Controlled Trial.Int. J. Environ. Res. Public Health202219231615810.3390/ijerph192316158 36498228
     [Google Scholar]
  66. ZouY. YanH. LiC. WenF. JizeX. ZhangC. LiuS. ZhaoY. FuY. LiL. LiuF. ChenJ. LiR. ChenX. TianM. A Pectic Polysaccharide from Codonopsis pilosula Alleviates Inflammatory Response and Oxidative Stress of Aging Mice via Modulating Intestinal Microbiota-Related Gut–Liver Axis.Antioxidants2023129178110.3390/antiox12091781 37760084
     [Google Scholar]
  67. SongJ. XuX. HeS. ZhangH. WangN. BaiY. LiB. ZhangS. Identification of the therapeutic effect and molecular mechanism of Coptis chinensis Franch. and Magnolia officinalis var. biloba on chronic gastritis.J. Ethnopharmacol.202331711686410.1016/j.jep.2023.116864 37393026
     [Google Scholar]
  68. LiJ. HuangQ. MaW. Hepatoprotective efficacy and interventional mechanism of JianPi LiShi YangGan formula in acute-onchronic liver failure.J. Ethnopharmacol.2024318Pt A116880
     [Google Scholar]
  69. LuX. LiJ. MaY. KhanI. YangY. LiY. WangY. LiuG. ZhangZ. YangP. ZhangC. Fermented Angelica sinensis activates Nrf2 signaling and modulates the gut microbiota composition and metabolism to attenuate D -gal induced liver aging.Food Funct.202314121523010.1039/D2FO01637K 36477974
     [Google Scholar]
  70. ShinM.R. LeeS.H. RohS.S. The Potential Hepatoprotective Effect of Paeoniae Radix Alba in Thioacetamide-Induced Acute Liver Injury in Rats.Evid. Based Complement. Alternat. Med.2022202211010.1155/2022/7904845 35126604
     [Google Scholar]
  71. ShiratoriM. ShojiT. KanazawaM. HongoM. FukudoS. Effect of rikkunshito on gastric sensorimotor function under distention.Neurogastroenterol. Motil.201123432332910.1111/j.1365‑2982.2010.01648.x
     [Google Scholar]
  72. ShiH.L. LiuC.H. DingL.L. ZhengY. FeiX.Y. LuL. ZhouX.M. YuanJ.Y. XieJ.Q. Alterations in serotonin, transient receptor potential channels and protease-activated receptors in rats with irritable bowel syndrome attenuated by Shugan decoction.World J. Gastroenterol.201521164852486310.3748/wjg.v21.i16.4852 25944998
     [Google Scholar]
  73. NgJ.J.J. LooW.M. SiahK.T.H. Associations between irritable bowel syndrome and non-alcoholic fatty liver disease: A systematic review.World J. Hepatol.202315792593810.4254/wjh.v15.i7.925 37547029
     [Google Scholar]
  74. PurssellH. WhorwellP.J. AthwalV.S. VasantD.H. Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?World J. Hepatol.202113121816182710.4254/wjh.v13.i12.1816 35069992
     [Google Scholar]
  75. ScaleraA. Di MinnoM.N. TarantinoG. What does irritable bowel syndrome share with non-alcoholic fatty liver disease?World J. Gastroenterol.201319335402542010.3748/wjg.v19.i33.5402 24023483
     [Google Scholar]
  76. WuS. WenF. ZhongX. DuW. ChenM. WangJ. Astragaloside IV ameliorate acute alcohol-induced liver injury in mice via modulating gut microbiota and regulating NLRP3/caspase-1 signaling pathway.Ann. Med.2023551221694210.1080/07853890.2023.2216942 37243569
     [Google Scholar]
  77. BeurelE. ToupsM. NemeroffC.B. The Bidirectional Relationship of Depression and Inflammation: Double Trouble.Neuron2020107223425610.1016/j.neuron.2020.06.002 32553197
     [Google Scholar]
  78. SimpsonC.A. Diaz-ArtecheC. ElibyD. SchwartzO.S. SimmonsJ.G. CowanC.S.M. The gut microbiota in anxiety and depression – A systematic review.Clin. Psychol. Rev.20218310194310.1016/j.cpr.2020.101943 33271426
     [Google Scholar]
  79. SheaS. LionisC. KiteC. AtkinsonL. ChaggarS.S. RandevaH.S. KyrouI. Non-alcoholic fatty liver disease (NAFLD) and potential links to depression, anxiety, and chronic stress.Biomedicines2021911169710.3390/biomedicines9111697 34829926
     [Google Scholar]
  80. SheaS. LionisC. KiteC. LagojdaL. UthmanO.A. DallawayA. AtkinsonL. ChaggarS.S. RandevaH.S. KyrouI. Non-alcoholic fatty liver disease and coexisting depression, anxiety and/or stress in adults: A systematic review and meta-analysis.Front. Endocrinol. (Lausanne)202415135766410.3389/fendo.2024.1357664 38689730
     [Google Scholar]
  81. TsaiS.T. NithiyananthamS. SatyanarayananS.K. SuK.P. Anti-inflammatory effect of traditional chinese medicine on the concept of mind-body interface.Adv. Exp. Med. Biol.2023141143545810.1007/978‑981‑19‑7376‑5_19 36949321
     [Google Scholar]
  82. WangQ. KuangH. SuY. SunY. FengJ. GuoR. ChanK. Naturally derived anti-inflammatory compounds from Chinese medicinal plants.J. Ethnopharmacol.2013146193910.1016/j.jep.2012.12.013 23274744
     [Google Scholar]
  83. HuY. MaoA. YuZ. HeK. Anti-endotoxin and anti-inflammatory effects of Chinese herbal medicinal alkaloid ingredients in vivo.Microb. Pathog.201699515510.1016/j.micpath.2016.08.006 27498361
     [Google Scholar]
  84. ZouW. GongL. ZhouF. LongY. LiZ. XiaoZ. OuyangB. LiuM. Anti-inflammatory effect of traditional Chinese medicine preparation Penyanling on pelvic inflammatory disease.J. Ethnopharmacol.202126611340510.1016/j.jep.2020.113405 32979412
     [Google Scholar]
  85. LiuJ. SunY. How does Chinese medicine target cytokine imbalance in rheumatoid arthritis?Chin. J. Integr. Med.2013191187488010.1007/s11655‑013‑1620‑6 24170633
     [Google Scholar]
  86. XieZ. JiangN. LinM. HeX. LiB. DongY. ChenS. LvG. The mechanisms of polysaccharides from tonic chinese herbal medicine on the enhancement immune function: A Review.Molecules20232821735510.3390/molecules28217355 37959774
     [Google Scholar]
  87. BurnsJ.J. ZhaoL. TaylorE.W. SpelmanK. The influence of traditional herbal formulas on cytokine activity.Toxicology2010278114015910.1016/j.tox.2009.09.020 19818374
     [Google Scholar]
  88. SunK. WuL. WangS. DengW. Antitumor effects of Chinese herbal medicine compounds and their nano-formulations on regulating the immune system microenvironment.Front. Oncol.20221294933210.3389/fonc.2022.949332 36212483
     [Google Scholar]
  89. MartelJ. ChangS.H. KoY.F. HwangT.L. YoungJ.D. OjciusD.M. Gut barrier disruption and chronic disease.Trends Endocrinol. Metab.202233424726510.1016/j.tem.2022.01.002 35151560
     [Google Scholar]
  90. LiM. LiM. LeiJ. WuY. LiZ. ChenL. ZhouC. SuJ. HuangG. HuangX. ZhengX. Huangqin decoction ameliorates DSS-induced ulcerative colitis: Role of gut microbiota and amino acid metabolism, mTOR pathway and intestinal epithelial barrier.Phytomedicine202210015405210.1016/j.phymed.2022.154052 35344714
     [Google Scholar]
  91. WuY. ZhengY. WangX. TangP. GuoW. MaH. ZhangA. LiD. XieY. WangC.Z. YaoH. WanJ.Y. YuanC.S. Ginseng-Containing Sijunzi Decoction Ameliorates Ulcerative Colitis by Orchestrating Gut Homeostasis in Microbial Modulation and Intestinal Barrier Integrity.Am. J. Chin. Med.202351367769910.1142/S0192415X23500325 36883990
     [Google Scholar]
  92. JinL. DengL. BartlettM. RenY. LuJ. ChenQ. PanY. WangH. GuoX. LiuC. A novel herbal extract blend product prevents particulate matters-induced inflammation by improving gut microbiota and maintaining the integrity of the intestinal barrier.Nutrients20221410201010.3390/nu14102010 35631153
     [Google Scholar]
/content/journals/cchts/10.2174/0113862073302157240920115002
Loading
Yunpi Rougan Prescription in Treating Constipation-Predominant IBS: Clinical Observation and Gut Microbiota Effects
Comb Chem High Throughput Screen 28, 2810 (2025); https://doi.org/10.2174/0113862073302157240920115002
/content/journals/cchts/10.2174/0113862073302157240920115002
/content/journals/cchts/10.2174/0113862073302157240920115002
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): 16SrDNA; clinical effect; Constipation-Predominant irritable bowel syndrome; gut microbiota; liver-depression and spleen-deficiency syndrome; YunPi RouGan prescription

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test